Total neoadjuvant therapy for initially inoperable pancreatic cancer: A systematic review of phase 2-3 studies
- PMID: 34509562
- DOI: 10.1016/j.radonc.2021.09.001
Total neoadjuvant therapy for initially inoperable pancreatic cancer: A systematic review of phase 2-3 studies
Abstract
Introduction: Patients with initially inoperable non-metastatic pancreatic cancer (PC) have a poor prognosis, often similar to those with metastatic disease. Neoadjuvant chemotherapy (CT) plus concomitant or sequential radiotherapy (RT) may cause tumor shrinkage and allow for radical surgery. We pooled data of studies in which patients with locally advanced (unresectable) or borderline resectable PC were treated with a course of induction (or consolidation) CT followed or preceded by neoadjuvant CTRT regimen.
Materials and methods: We searched articles, including phase 2 or 3 studies, published in English from 2010 up to December 2020 in PubMed, SCOPUS, the Cochrane Library, and EMBASE. The primary outcomes were the pooled radical and R0 resection rates, median PFS and OS of included patients (those included in the intent to treat analysis).
Results: A total of 28 studies were finally considered eligible for inclusion in quantitative analysis for a total of 2446 patients with locally advanced/borderline resectable PC. Overall the pooled rate of resection was 29.7% (95%CI 26.7-32.8%). In patients who completed the CT + CTRT program, the overall resection rate was 31.8% (95% 28.4-35.4%). After exclusion of studies that included resectable PCs, the overall resection rate was 19.9% (95%CI 17.3-22.7%). In studies were all patients had unresectable PC (n = 20 studies), the resection rate was 12.1% (95%CI 10-14.5%). In two studies that enrolled all borderline resectable PCs the resection rate was 59.2% (95%CI 48.9-68.8%). The pooled R0 resection rate was 68.7% (95%CI 64.7-72.3%). The median pooled OS was 15.7 months (95%CI 14-17.2 months) and the median pooled PFS was 10.7 (95%CI 9.3-12.1 months).
Conclusions: Surgery is a treatment option in about one third of patients with initially inoperable PC, following total neoadjuvant therapy. In unresectable cases the resection rate was 12%. Median OS and PFS rates were comparable with historical data of advanced PCs. Optimal integration and sequence of chemo- and radiotherapy in unresectable PC must still be defined.
Keywords: Chemoradiotherapy; Inoperable; Pancreatic cancer; Total neoadjuvant.
Copyright © 2021 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies.Pancreas. 2015 May;44(4):515-21. doi: 10.1097/MPA.0000000000000314. Pancreas. 2015. PMID: 25872127 Review.
-
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.JAMA Oncol. 2018 Jul 1;4(7):963-969. doi: 10.1001/jamaoncol.2018.0329. JAMA Oncol. 2018. PMID: 29800971 Free PMC article. Clinical Trial.
-
Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre.ESMO Open. 2020 Nov;5(6):e000929. doi: 10.1136/esmoopen-2020-000929. ESMO Open. 2020. PMID: 33229503 Free PMC article.
-
How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.Eur Radiol. 2022 Jan;32(1):56-66. doi: 10.1007/s00330-021-08108-0. Epub 2021 Jun 25. Eur Radiol. 2022. PMID: 34170366
-
Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis.Ann Surg Oncol. 2021 Dec;28(13):8297-8308. doi: 10.1245/s10434-021-10276-8. Epub 2021 Jun 17. Ann Surg Oncol. 2021. PMID: 34142290 Free PMC article.
Cited by
-
Ablative Radiotherapy (ART) for Locally Advanced Pancreatic Cancer (LAPC): Toward a New Paradigm?Life (Basel). 2022 Mar 22;12(4):465. doi: 10.3390/life12040465. Life (Basel). 2022. PMID: 35454956 Free PMC article. Review.
-
Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma.Clin Transl Radiat Oncol. 2024 Apr 12;47:100778. doi: 10.1016/j.ctro.2024.100778. eCollection 2024 Jul. Clin Transl Radiat Oncol. 2024. PMID: 38779525 Free PMC article.
-
Prognosis of Pancreatic Cancer Based on Resectability: A Single Center Experience.Cancers (Basel). 2023 Feb 9;15(4):1101. doi: 10.3390/cancers15041101. Cancers (Basel). 2023. PMID: 36831444 Free PMC article.
-
Total Neoadjuvant Therapy in Localized Pancreatic Cancer: Is More Better?Cancers (Basel). 2024 Jun 30;16(13):2423. doi: 10.3390/cancers16132423. Cancers (Basel). 2024. PMID: 39001485 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical